The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the expiry in key markets has introduced substantial uncertainty . Investors are now grappling with the impact of lower-cost altern